• Molecular NameMetolazone
  • SynonymMetolazona [INN-Spanish]; Metolazonum [INN-Latin]
  • Weight365.841
  • Drugbank_IDDB00524
  • ACS_NO17560-51-9
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.77
  • pkaN/A
  • LogD (pH=7, predicted)2.77
  • Solubility (experiment)0.0603 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.01
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds2
  • TPSA100.88
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIt is primarily used to treat congestive heart failure and high blood pressure.
  • Absorption_value64.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability65.0
  • Protein binding95.0
  • Volume of distribution (VD)1.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMinimal
  • Half life18 h
  • Excretionprimarily urine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma
  • LD50 (rat)N/A
  • LD50 (mouse)N/A